Schrödinger Appoints Veteran Pharmaceutical Executive Joel Lebowitz as Chief Financial Officer
November 15, 2018 at 05:30 pm IST
Share
Schrödinger announced the appointment of veteran pharmaceutical executive Joel Lebowitz as chief financial officer. Mr. Lebowitz, a longtime senior executive at Merck, brings to the company deep experience in finance and business development. Before joining Schrödinger, Mr. Lebowitz spent much of his career at Merck, serving most recently as global finance lead, project management. In that role, he led a global finance team in the successful divestiture of the Merck Consumer Care division. He also spent three years as Merck’s executive director for pipeline valuation and portfolio analysis, leading the group responsible for optimizing research investment and supporting portfolio planning and prioritization. Mr. Lebowitz’s other roles at Merck included executive director, corporate planning and management reporting, a position that gave him responsibility for developing the company’s budget, revenue forecasts, and long-range operating plan, and senior director, business development.
Schrodinger, Inc. operates a physics-based computational platform that enables the discovery of molecules for drug development and materials applications. The software platform is used by biopharmaceutical and industrial companies, academic institutions, and government laboratories around the world. The Company operates through two segments: Software and Drug Discovery. The Software segment is focused on selling its software to transform drug discovery across the life sciences industry, as well as to customers in materials science industries. The Drug Discovery segment is focused on building a diverse portfolio of preclinical and clinical programs, internally and through collaborations, that have advanced to various stages of discovery and development. The Company's pipeline of drug discovery programs includes SGR-1505 (MALT1 Inhibitor), SGR-2921 (CDC7 Inhibitor), SGR-3515 (WEE1 Inhibitor). Its software was used by researchers around the world at more than 1,760 academic institutions.